WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he playe ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | | ...

Aspira Women’s Health Inc. (NASDAQ:AWH) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Nicole Sandford – President and Chief Executive Officer Torsten Hombeck – Chief Financial Officer Conference Call Participants Sally Yanchus – Water Tower Research Andrew Brackmann – William Blair Operator Good afternoon, ladies and gentlemen, and welcome to Aspira’s Women’s Health, Incorporated Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-onl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |----- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---- ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Marlene McLennan - Interim Chief Financial Officer Conference Call Participants Sally Yanchus - Water Tower Research Operator Good afternoon ladies and gentlemen and welcome to Aspira Women's Health, Incorporated First Quarter 2023 Earnings Conference Call. During the pres ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 ___________________________ FORM 10-K T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) Dela ...

Financial Data and Key Metrics Changes - Total product revenue for 2022 was $8.2 million, a 20% increase from 2021, with a fourth quarter revenue of $2.1 million, up 16% year-over-year [24] - Gross profit margin improved to 53% for the year compared to 45% in 2021, and 57% for the fourth quarter compared to 55% in the same period last year [24] - Cash used in operations for 2022 was $32.2 million, with an anticipated cash usage for 2023 between $16 million and $19 million [26][15] Business Line Data and Key Metrics Changes - Test volumes increased to 21,423 for the year, a 23% increase, with fourth quarter volume increasing 18% to 5,642 tests [24] - Ova1Plus test volumes contributed significantly to revenue growth, with the average unit price decreasing to $372 for the year [24][29] Market Data and Key Metrics Changes - The company is actively pursuing payer adoption and fair pricing for the OvaSuite test portfolio, achieving important milestones in 2022 [12] - OvaWatch received coverage from a leading global payer shortly after its launch, indicating positive market reception [12] Company Strategy and Development Direction - The company is focused on growth, innovation, and operational excellence, with a commitment to transparency and effective resource utilization [5] - Plans for 2023 include engaging in high-impact media and refining sales strategies to enhance provider adoption [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for OvaWatch and the overall market for ovarian cancer diagnostic tools, emphasizing the critical need for better diagnostics [27] - The company is navigating challenging market conditions while maintaining a focus on revenue growth and operational efficiency [15][49] Other Important Information - The company reduced its workforce by nearly 30%, resulting in significant payroll savings for 2023 [14] - A $12.5 million equity placement was established to enhance liquidity [15] Q&A Session Summary Question: What is the outlook for OvaWatch's average selling price (ASP) following national payer agreements? - Management indicated that establishing payer relationships takes time, but they are optimistic about aligning OvaWatch's ASP with Ova1Plus by the end of the year [29] Question: How are discussions progressing with potential partners for OvaWatch? - Management noted that reimbursement is a key factor for potential partners, and they are actively engaging with interested parties [31][32] Question: What needs to happen from a development and regulatory perspective before launching the endometriosis test? - The availability of high-quality samples for validation remains a challenge, and management is exploring various regulatory paths for the test [36] Question: What feedback is being received on OvaWatch, and is there any cannibalization of Ova1Plus? - Management reported no cannibalization of Ova1Plus and positive feedback from physicians regarding OvaWatch's utility [39] Question: What is the timeline for the serial monitoring assay for OvaWatch? - The company aims to launch the serial monitoring test in the second half of 2023, with ongoing clinical studies supporting its development [43]

Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Robert Beechey - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair & Company Operator Good morning, ladies and gentlemen, and welcome to Aspira Women’s Health Incorporated Third Quarter 2022 Conference ...